Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach

British Journal of Clinical Pharmacology

Volumn 76, Issue 6, 2013, Pages 868-879

  Bartels, Christian ^a   Looby, Michael ^a   Sechaud, Romain ^a   Kaiser, Guenther ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

chronic obstructive pulmonary disease; glycopyrronium; lung absorption; modelling; pharmacokinetics

Indexed keywords

ACTIVATED CARBON; GLYCOPYRRONIUM BROMIDE; INDACATEROL;

AREA UNDER THE CURVE; ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN EXPERIMENT; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; STEADY STATE;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; GLYCOPYRRONIUM; LUNG ABSORPTION; MODELLING; PHARMACOKINETICS;

ABSORPTION; ADMINISTRATION, INHALATION; BIOLOGICAL AVAILABILITY; CHARCOAL; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; GLYCOPYRROLATE; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRAVENOUS; LUNG; MODELS, BIOLOGICAL; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84887130215     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12118     Document Type: Article

References (27)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2011. Updated December 2011. Available at http://www.goldcopd.org (last accessed 5 December 2012).
2. Lipworth BJ,. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996; 42: 697-705.
3. Van den Bosch JM, Westermann CJJ, Aumann J, Edsbäcker S, Tönnesson, Selroos O,. Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos 1993; 14: 455-459.
4. Compton C, Patalano F, Fedele MJ, McBryan D,. The right treatment for the right patient: the Novartis view on COPD. Nature 2012; 489 (Suppl. 7417): S1-48. Available at http://www.nature.com/nature/journal/v489/n7417-supp/index. html#top (last accessed 4 April 2013).
5. Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, Barnes PJ,. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005; 128: 1974-1979.
6. D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T,. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011; 12: 156. doi: 10.1186/1465-9921-12-156
7. Fogarty C, Hattersley H, Di Scala L, Drollmann A,. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2011; 105: 337-342.
8. Kerwin E, Hébert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D,. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012; 40: 1106-1114.
9. Verkindre C, Fukuchi Y, Flemale A, Takeda A, Overend T, Prasad N, Dolker M,. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010; 104: 1482-1489.
10. Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Güçlü SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK,. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010; 23: 438-444.
11. Tronde A, Bosquillon C, Forbes B,. The isolated perfused lung for drug absorption studies. In: Drug Absorption Studies, eds, Ehrhardt C, Kim KJ,: Springer US, 2008; 135-163.
12. Sechaud R, Sudershan M, Perry S, Hara H, Drollmann A, Karan R, Di Scala L, Biswal S, Patterson B, Kaiser G,. Efficient deposition and sustained lung concentrations of NVA237 after inhalation via the Breezhaler®device in man. Eur Respir J 2012; 40: (Suppl. 56): 889s.
13. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ,. NONMEM users guides, parts I-VII. NONMEM Project Group. San Francisco, CA: University of California, 1992.
14. Lindbom L, Pihlgren P, Jonsson EN,. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-257.
15. Gelfand AE, Hills SE, Racine-Poon A, Smith AFM,. Illustration of bayesian inference in normal data models using Gibbs sampling. J Am Stat Assoc 1990; 85: 972-985.
16. th edition. Br J Pharmacol 2011; 164(Suppl 1): S1-S2.
17. Derks MGM, van den Berg BTJ, van der Zee JS, Braat MCP, van Boxtel CJ,. Biphasic effect-time courses in man after formoterol inhalation: eosinopenic and hypokalemic effects and inhibition of allergic skin reactions. J Pharmacol Exp Ther 1997; 283: 824-832.
18. Potocka E, Baughman RA, Derendorf H,. Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol 2011; 51: 1015-1024.
19. Gaz C, Cremona G, Panunzi S, Patterson B, De Gaetano A,. A geometrical approach to the PKPD modelling of inhaled bronchodilators. J Pharmacokinet Pharmacodyn 2012; 39: 415-428.
20. Olsson B, Bondesson E, Bongstrom L, Edsbäcker S, Eirefelt S, Ekelund K, Gustavsson L, Hegelund-Myrbäck T,. Pulmonary drug metabolism, clearance, and absorption. In: Controlled Pulmonary Drug Delivery, eds, Smyth HDC, Hickey AJ,. New York, NY: Springer, 2011; 21-50.
21. Upton RN, Doolette DJ,. Kinetic aspects of drug disposition in the lungs. Clin Exp Pharmacol Physiol 1999; 26: 381-391.
22. Ali-Melkkilä T, Kaila T, Kanto J,. Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. Acta Anaesthesiol Scand 1989; 33: 513-517.
23. Rautakorpi P, Manner T, Ali-Melkkilä T, Kaila T, Olkkola K, Kanto J,. Pharmacokinetics and oral bioavailability of glycopyrrolate in children. Pharmacol Toxicol 1998; 83: 132-134.
24. Sechaud R, Renard D, Zhang-Auberson L, Motte SL, Drollmann A, Kaiser G,. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther 2012; 50: 118-128.
25. Beeh K, Singh D, Di Scala L, Drollmann A,. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012; 7: 503-513.
26. Arievich H, Overend T, Renard D, Gibbs M, Alagappan V, Looby M, Banerji D,. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med 2012; 12: 74. doi: 10.1186/1471-2466-12-74
27. Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G,. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012; 106: 970-979.